According to the industry, yesterday (26th) the HIRA's Cancer Drugs Benefit Appraisal Committee recognized the appropriateness of immuno-cancer drug Keytruda (Pembrolizumab)'s ▲ bladder cancer 2nd or higher ▲ typical Hodgkin lymphoma solo therapy that recurred after 3rd treatment.

In fact, NSCLC, Non-small Cell Lung Cancer's indication of primary solo and combined therapy failed to pass the Cancer Drugs Benefit Appraisal Committee on the eighth challenge.

This is likely to make it virtually difficult to expand the benefit of Keytruda's indications of lung cancer. It has been discussing the benefit expansion since September 2017. It's been almost four years now. The biggest challenge at